Proving the principle: dendritic cell-based vaccines in urogenital cancers

Immunotherapy for prostate cancer: biology and therapeutic approaches

Antigen-specific immunity and tumor inflammation after vaccination with BPX-101, a drug-activated dendritic cell vaccine for metastatic castration-resistant prostate cancer (mCRPC).

Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research

Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer

Recent advances in immunotherapy for the treatment of prostate cancer

Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC).

Immunotherapy for the treatment of prostate cancer

Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer